BCAX Key Statistics, Chart & Performance
The current stock price of BCAX is 16.75 USD. In the past month the price decreased by -6.84%. In the past year, price increased by 38.32%.
BCAX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BCAX. When comparing the yearly performance of all stocks, BCAX is one of the better performing stocks in the market, outperforming 75.35% of all stocks.
BCAX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCAX. BCAX has a great financial health rating, but its profitability evaluates not so good.
BCAX Financial Highlights
Over the last trailing twelve months BCAX reported a non-GAAP Earnings per Share(EPS) of -2.24. The EPS decreased by -302.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.61% | ||
| ROE | -30.17% | ||
| Debt/Equity | 0 |
BCAX Forecast & Estimates
16 analysts have analysed BCAX and the average price target is 33.22 USD. This implies a price increase of 98.35% is expected in the next year compared to the current price of 16.75.
BCAX Ownership
BCAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About BCAX
Company Profile
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Company Info
BICARA THERAPEUTICS INC
116 Huntington Avenue Suite 703
Boston MASSACHUSETTS US
Employees: 55
Phone: 16174684219
BICARA THERAPEUTICS INC / BCAX FAQ
What does BICARA THERAPEUTICS INC do?
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
What is the stock price of BICARA THERAPEUTICS INC today?
The current stock price of BCAX is 16.75 USD. The price increased by 0.36% in the last trading session.
Does BCAX stock pay dividends?
BCAX does not pay a dividend.
How is the ChartMill rating for BICARA THERAPEUTICS INC?
BCAX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of BICARA THERAPEUTICS INC (BCAX) based on its PE ratio?
BICARA THERAPEUTICS INC (BCAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.24).
When does BICARA THERAPEUTICS INC (BCAX) report earnings?
BICARA THERAPEUTICS INC (BCAX) will report earnings on 2026-03-24.
Can you provide the short interest for BCAX stock?
The outstanding short interest for BICARA THERAPEUTICS INC (BCAX) is 17.77% of its float.